SynAct Pharma
SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company develops a portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases. SynAct Pharma's business model focuses on advancing projects to clinical proof-of-concept, specifically targeting Phase 2 studies, before entering commercial agreements with major pharmaceutical companies. The company is listed on Nasdaq Stockholm and operates through its subsidiaries in Denmark and Switzerland.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes oral and injectable compounds for inflammation resolution.
Services related to advancing clinical trials to Phase 2.
Collaborative projects with research institutions.
Customers
SynAct Pharma primarily targets pharmaceutical companies interested in innovative treatments for autoimmune and inflammatory diseases. Their customer base includes large pharmaceutical firms looking to license new therapies after proof-of-concept is established. Additionally, they collaborate with research institutions for the development of new drug candidates. The company's focus on non-suppressive therapies appeals to companies seeking alternatives to traditional immune-suppressive treatments.
They license therapies post proof-of-concept for autoimmune diseases.
Collaborate on developing new drug candidates.
Interested in non-suppressive inflammation therapies.
Strategy
SynAct Pharma's strategic priorities include advancing its lead compound, resomelagon, through Phase 2 clinical trials and securing strategic partnerships with major pharmaceutical companies. The company aims to expand its therapeutic applications to include acute inflammation due to viral infections. By focusing on non-suppressive therapies, SynAct Pharma seeks to differentiate itself in the competitive biotech landscape. The company is also exploring opportunities for geographic expansion to enhance its market reach.
To establish proof-of-concept and attract partners.
To address larger markets such as viral infections.
To facilitate commercialization and market entry.
Geography
SynAct Pharma is headquartered in Lund, Sweden, and operates through subsidiaries in Denmark and Switzerland. The company is listed on Nasdaq Stockholm, providing it with a strong presence in the European market. Its strategic location in Scandinavia allows for collaboration with leading research institutions across Europe. The company's geographic focus supports its business model by facilitating access to European regulatory bodies and potential partners.
Risks
Key risks for SynAct Pharma include the inherent uncertainties of drug development, such as clinical trial outcomes and regulatory approvals. The company also faces competition from other biotech firms developing similar therapies. Financial risks include the need for continuous funding to support R&D activities. Additionally, currency fluctuations and changes in regulatory requirements could impact operations. The company's reliance on partnerships for commercialization poses a strategic risk if suitable partners are not secured.
- Clinical trial outcomesImpact: CriticalLikelihood: Medium
Uncertainty in achieving desired results.
- Funding requirementsImpact: HighLikelihood: High
Need for continuous investment in R&D.
- Regulatory approvalImpact: HighLikelihood: Medium
Complex and evolving requirements.
- CompetitionImpact: HighLikelihood: Medium
Other firms developing similar therapies.
Accounting
Judgemental itemsImpacts financial results and projections.
Affects balance sheet and financial health.
Crucial for financial projections and reporting.
Similar listed companies
Publicly listed companies with a comparable business focus.
Synsam
SYNSAM · Consumer Discretionary
Synsam Group is a leading optician group in the Nordic region, offering a wide range of products and services for eye health and eye fashion.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Last updated: 24/09/2026